Krystal Biotech initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage of Krystal Biotech with an Overweight rating and $160 price target. The firm is anticipating a very strong Vyjuvek product launch, with over $1B in peak world-wide revenue potential which, along with pipeline optionality, make Krystal Biotech an attractive name to own, the analyst tells investors in a research note. The firm adds it will continue to monitor long-term Vyjuvek per-patient utilization trends since that’s an important unknown to plug into outer year estimates.